At 10.15am, the company's share price was up two sen or 3.77% to 55 sen on the back of 31 million shares traded.
Earlier in the day, the stock had risen to a trading high of 56.6 sen apiece amid rapidly rising turnover.
Bintai had said in a filing with Bursa Malaysia yesterday that its healthcare unit was partnering Scientillence to develop and market medical products in the hemodialysis market.
The joint venture would also work towards developing, investing, acquiring or owning dialysis centres and other renal care businesses in Malaysia and Southeast Asia.
Scientillence, owned by the ex-CEO and chairman of hospital group Pantai Holdings Bhd Tan Sri Lim Tong Yong, is the sole manufacturer of dialyser (artificial kidney) in Malaysia as well as Southeast Asia.
The partnership between Bintai Healthcare and Scientillence will facilitate Bintai Group to tap into the hemodialysis market as part of its business strategies to widen its range of products and services including distribution of medical devices and healthcare solutions in Malaysia.